ESC 365 - Safety and effectiveness of sodium-glucose co-transporter 2 inhibitors in active cancer patients with heart failure: results of the observational TOSCA trial

ESC Professional Premium Access

Safety and effectiveness of sodium-glucose co-transporter 2 inhibitors in active cancer patients with heart failure: results of the observational TOSCA trial

Session: Caring for the patient with cancer and heart disease: the clinical perspective

Topic: Cardio-Oncology

Speaker: Doctor M. Canale (Lido Di Camaiore, IT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Maria Laura Canale

Versilia Hospital, Lido Di Camaiore (Italy)

2 presentations

0 follower

7 more presentations in this session

Cardiovascular events and consequent risk of death in hematopoietic stem cell transplant recipients

Speaker: Doctor G. Stronati (Ancona, IT)

Socioeconomic status and cardiovascular mortality in over 170,000 cancer survivors: a population-based cohort study

Speaker: Doctor Y. Kim (Seoul, KR)

Routine application of cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy

Speaker: Mr T. Lerchner (Essen, DE)

Cardiological monitoring during BTK inhibitor, ICI, and RAF/MEK inhibitor therapy: the single-center prospective registry for cardiovascular events under new cancer therapies (RECENT)

Speaker: Doctor L. Seuthe (Cologne, DE)

New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.

Speaker: Doctor N. Osataphan (Chiang Mai, TH)

Access the full session

Caring for the patient with cancer and heart disease: the clinical perspective

Speakers: Doctor M. Canale, Doctor G. Stronati, Doctor Y. Kim, Mr T. Lerchner, Doctor L. Seuthe...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources